ArticleMolecular neurobiology2026
Impact of Losartan Nanoparticles on Carbon Tetrachloride-induced Cerebellar Injury in Rats: Association with Alterations in RIPK1/RIPK3/MLKL Necroptosis Markers.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbon tetrachloride (CCL₄) is a lipophilic industrial solvent metabolized by cytochrome P450 enzymes. Its rapid diffusion across membranes facilitates widespread tissue distribution, including the brain, where it induces oxidative stress and alters the expression of necroptosis-related markers, including tumor necrosis factor-alpha (TNF-α). Losartan, an angiotensin II receptor antagonist, has demonstrated attenuation of cerebellar injury in many neurodegenerative diseases. This study evaluated the potentials of losartan and its nanoparticle formulation against CCL₄-induced cerebellar injury. Twenty-four adult male Sprague-Dawley rats were assigned into four groups: Control, CCL₄, Losartan, and Losartan potassium nanoparticles (LP-NPs)-treated groups. Oxidative stress parameters, quantitative Real time- PCR (qRT-PCR) for Tnf-α, receptor interacting protein kinase 1 (Ripk1), receptor interacting protein kinase 3 (Ripk3), and mixed lineage kinase domain-like protein (Mlkl), along with histological and immunohistochemical (IHC) assessments, were performed. CCL₄ exposure significantly elevated malondialdehyde (MDA) while reducing superoxide dismutase (SOD), reduced glutathione (GSH), and catalase. Molecular study shows upregulation of mRNA expression of Tnf-α, Ripk1, Ripk3, and Mlkl, which correlates with alterations in necroptosis-related marker expression. IHC showed marked increases in RIPK1, RIPK3, Glial Fibrillary Acidic Protein (GFAP), and Ionized calcium-binding adaptor molecule1 (Iba1) immunoreactivity, with a concomitant decrease in caspase-8. Histologically, CCL₄ induced severe cerebellar alterations, including reduced myelinated fiber area, Purkinje cell loss, and granular layer thinning. Both Losartan- and LP-NPs-treated groups significantly mitigated these biochemical, molecular, and histological changes, with LP-NPs exerting greater observed effects in histological parameters and selected IHC markers. Both treatments produced comparable reductions in qRT-PCR mRNA expressions of Tnf-
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.